A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D

开始日期2019-01-30

申办/合作机构

4D Pharma Plc

NCT03721107 / Completed临床2期

A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D

A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).

开始日期2018-10-11

申办/合作机构

4D Pharma Plc

100 项与 Blautix 相关的临床结果

登录后查看更多信息

100 项与 Blautix 相关的转化医学

登录后查看更多信息

100 项与 Blautix 相关的专利（医药）

登录后查看更多信息

项与 Blautix 相关的文献（医药）

2024-03-03·Expert opinion on investigational drugs

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

Review

作者: Mozaffari, Shilan ; Nikfar, Shekoufeh ; Abdollahi, Mohammad

INTRODUCTION:

Irritable bowel syndrome (IBS) has a significant impact on society and quality of life. Current treatments are ineffective, and new investigational drugs are necessary.

AREAS COVERED:

Numerous potential therapies are developing, targeting different areas such as cannabinoid signaling, opioid receptors, tachykinin (NK2) receptors, β3-adrenergic receptors, intestinal microbiota, inflammation, and 5HT receptors. Clinical trial evidence has shown that loperamide, eluxadoline, alosetron, ramosetron, bile acid sequestrants, and rifaximin can modulate GI alterations and benefit patients with IBS-D. Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, solabegron, vibegron, olorinab, ebastine, and ORP-101 have demonstrated possible effects but remain confirmed.

EXPERT OPINION:

Individuals with IBS-D require cost-effective treatment options that do not impede their productivity or that of their caregivers. This is necessary for consistent healthcare and improved quality of life. Therefore, we should focus on developing new, efficient, and affordable medications for IBS-D. The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment.

2023-01-01·Alimentary pharmacology & therapeutics

Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome

Article

作者: Treasure, F. Peter ; Markinson, Louise ; Lacy, Brian E. ; Stevenson, Alex ; Quigley, Eamonn M. M.

Summary:

Background:

MRx1234 is a live biotherapeutic product that contains a strain of Blautia hydrogenotrophica. It is in development for the treatment of irritable bowel syndrome (IBS).

Aims:

To assess the efficacy and safety of MRx1234 in patients with IBS with predominant constipation (IBS‐C) or diarrhoea (IBS‐D)

Methods:

We conducted a multicentre, randomised, double‐blind, placebo‐controlled, phase 2 trial. Patients aged 18–70 years in two parallel cohorts (IBS‐C; IBS‐D) were randomised (1:1) to MRx1234 or placebo for 8 weeks. The primary efficacy endpoint was overall responder rate—a composite of improved bowel habit (IBS‐C: stool frequency; IBS‐D: stool consistency) and abdominal pain intensity—for ≥50% of the treatment period in each cohort. Statistical testing was at a one‐sided 0.10 significance level.

Results:

Of 366 randomised patients (164 IBS‐C; 202 IBS‐D), 365 received any study medication (177 MRx1234, 188 placebo). Numerically, although not statistically significantly different, more patients who received MRx1234 than placebo were overall responders in the IBS‐C (25.0% vs. 17.1%) and IBS‐D (23.4% vs. 17.8%) cohorts. Similar results were observed in the additional combined cohort analysis (24.1% vs. 17.5%; p = 0.063). For the components of the primary endpoint, significantly more patients on MRx1234 than placebo reported improvement in bowel habit in the IBS‐C, IBS‐D and combined cohorts, while improvements in abdominal pain were observed in each cohort. The safety profile of MRx1234 was similar to placebo.

Conclusions:

MRx1234 has the potential to become a novel, safe treatment option for patients with IBS‐C or IBS‐D, and for those who have mixed symptoms or transition between subtypes.ClinicalTrials.gov #NCT03721107.

项与 Blautix 相关的新闻（医药）

2023-04-28

·创鉴汇

被美国FDA认可！人体内的这群“小东西”居然能治病？

▎药明康德内容团队编辑就在昨天，微生物组疗法又迎来了一项重大里程碑，美国FDA批准Seres Therapeutics公司口服微生物组疗法Vowst（SER-109）上市，用于预防成人患者艰难梭菌感染（CDI）复发。SER-109旨在帮助患者恢复胃肠道内微生物的多样性。艰难梭菌是一种抗生素耐药菌，可导致腹痛、腹泻以及结肠损伤，已被美国疾病控制和预防中心（CDC）列为紧迫威胁之一。截至目前，美国FDA仅批准的两款微生物组疗法Rebyota（于去年11月获批）和Vowst均用于预防CDI复发，且不含抗生素，这缓解了日益严峻的微生物耐药问题。01什么是微生物组疗法栖息在人体内的微生物和健康息息相关。胃肠道拥有非常复杂的微生物群落，它们各司其职，帮助宿主合成必备的营养元素，参与代谢和神经信号调节，激活免疫应答，是人体健康的“晴雨表”。一旦微生物组失衡，疾病可能悄然而至。研究表明，紊乱的肠道菌群与肥胖、2型糖尿病、非酒精性脂肪肝病（NAFLD）等多种代谢疾病的发病机制有关，还有可能是炎症性肠病（IBD）进展的关键因素。IBD患者体内的肠道菌群的构成发生变化，表现在如大肠杆菌等兼性厌氧菌的增加和专性厌氧菌的减少，同时微生物组的多样性也发生锐减。此外，微生物组还会通过肠-脑轴影响机体的大脑结构，造成中枢神经系统疾病的发生......图片来源：123RF微生物世界隐藏着太多未解之谜，既然菌群失衡是导致疾病的“罪魁祸首”，那么利用“好”的微生物调节菌群也不失为疾病治疗方案的一种选择。02微生物组药物临床管线先后获美国FDA批准上市的两款药物拉开了微生物组疗法从临床迈入商业化应用的序幕，其安全性和有效性得到了证实。近几年，越来越多的新锐公司和科研机构加入，希望挖掘寄生在人体的微生物组和疾病之间的关联，研发新药，提供新的治疗方案。测序技术的进步及器官芯片的应用加快了微生物组疗法的研发进程，但如何确定与疾病相关的细菌种类仍然是个问题。根据多渠道信息汇总整理和统计，目前56%的微生物组疗法处在临床前阶段。和5年前相比有了明显的进步，约32%的药物已经进入临床试验，另有3%的药物成功上市。从疾病类型来看，胃肠道疾病是现在药物研发分布最多的治疗领域。随着微生物组和疾病机制之间的关联不断被揭开，微生物组也被视为治疗癌症、细菌感染、2型糖尿病等代谢疾病的方法。7款药物已经在美国、澳大利亚等地上市，多针对CDI感染和消化系统疾病。胃肠道疾病：多针对IBD和IBS目前共有35种微生物组疗法已经迈入临床试验阶段，多数疗法针对炎症性肠病（IBD）和肠易激综合征（IBS）。克罗恩病是IBD的一种亚型，会使患者消化道出现炎症。4D pharma研发的Thetanix可治疗儿童克罗恩病，这是一种单菌株人类肠道共生细菌，具有抗炎机制，可以改善肠道粘膜屏障功能，从而减少突破粘膜屏障的病原体，目前已经完成1b期临床试验。针对IBS，该公司研发了Blautix，可降低肠道中的二氧化碳和氢气水平，相应地减少了IBS患者肠道内的气体，减轻腹胀和腹痛的频率。另有3款药物进展较快，目前已经进入3期临床试验阶段。其中，瑞典公司Infant Bacterial Therapeutics研发的一款预防早产儿坏死性小肠结肠炎的活细菌疗法IBP-9414，含有活性化合物罗伊氏乳杆菌，这是一种天然存在于母乳中的有益菌，可以改善早产儿脆弱的肠道功能。平衡微生物组，对抗细菌感染抗感染也是微生物组疗法重点关注的领域之一。传统抗生素无差别杀死体内“好坏”各种细菌，利用微生物对抗致病细菌可以避免扰乱体内微生物组，阻止“坏”的抗耐药性细菌在体内定居，加重疾病。目前有近20款针对细菌感染的微生物药物进入临床试验阶段，多数药物用于治疗CDI，此外大肠杆菌感染和尿路感染（UTI）也是较受关注的疾病类型。抗癌新兴领域：和检查点抑制剂联用增强免疫应答近年来，微生物组疗法抗癌已经成为了一个热门趋势。发表在《科学》杂志的多项研究表明，微生物组疗法和检查点抑制剂联用，有望增强肿瘤对免疫疗法的应答。研究催生了许多公司和大型药企的合作，希望通过药物联用，增加对检查点抑制剂产生应答的患者数量。4D pharma研发的MRx0518疗法是一种口服的鸡肠球菌菌株，与默沙东（MSD）抗PD-1疗法Keytruda联用，在治疗肾细胞癌的1/2期临床试验中达到主要疗效终点，在试验队列扩展阶段还将适应症扩展至其他多个实体瘤。此外，4D pharma还与辉瑞和德国默克（Merck KGaA）合作开展临床试验，与Bavencio联用治疗局部晚期或转移性尿路上皮癌患者。03跨国药企纷纷布局跨国药企在该领域又有什么动作？其实近5年来，微生物组疗法的潜力得到了诸如罗氏、武田、辉瑞等跨国药企的关注，它们携手微生物组疗法公司，共同推进创新药物研发。罗氏（Roche）旗下的基因泰克（Genentech）与Novome Biotechnologies达成一项多年研究合作和授权协议，将利用Novome专有的基因工程微生物药物（GEMMs）平台来发现、改造和开发细菌菌株，用于治疗IBD等疾病。Novome通过对食品中常见的乳酸乳球菌进行工程设计，开发了GEMMs技术平台。这些工程化细菌可在人体肠道中可控和强效定植，从而递送靶向治疗药物。根据协议，Novome从基因泰克获得1500万美元的预付款，与未来达5.9亿美元的潜在开发和商业里程碑付款，以及产品日后净销售的分级特许权使用费。葛兰素史克（GSK）与Eligo Bioscience达成合作协议，共同推进一种基于CRISPR的痤疮疗法。Eligo设计了一种噬菌体衍生的颗粒携带DNA切割CRISPR系统，只在有害的特定细菌的基因组中进行DNA双链切割从而将其杀灭，而有益细菌则完好无损。根据协议，Eligo将有资格获得最高不超过2.24亿美元的许可费和潜在里程碑付款。吉利德科学（Gilead Sciences）与Second Genome达成为期四年的战略合作，以开发新的生物标志物，共同确定与吉利德科学研发管线中5种在研疗法的临床应答相关的生物标志物，并开发治疗炎症性肠病（IBD）的潜在新靶点和候选药物。Second专有的微生物组发现平台能够利用微生物组学的最新见解帮助细分患者，并优化适合患者的潜在疗法。根据协议，Second获得3800万美元的前期付款，和约3亿美元的潜在里程碑付款，以及就所开发药物的销售额分成。写在最后此次口服粪便微生物疗法获FDA批准的好消息是一剂强心针，证明了微生物组疗法研发领域的价值与潜力。正如知名风投机构Flagship Pioneering的创始人兼首席执行官Noubar Afeyan博士在公开信中所述，先驱性的科学研究需要不断失败和长期经验的积累，才能一飞冲天，完成突破。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。参考资料[1] Yong Fan & Oluf Pedersen. Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology,2020. doi: https://doi.org/10.1038/s41579-020-0433-9[2] FDA批准首个粪便微生物产品，这个领域能否成为新药开发的下一个宝藏？Retrieved Dec. 3 from https://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==&mid=2247535386&idx=1&sn=c52dae6f5dbeeae1e0d5218b9b6fa702&chksm=f96dcc22ce1a45342ac2088f71bb8ba664154ae86b0f4678cc832cf06867b26dc6800b5f345e#rd[3] Microbiome Modulator Drugs – The New Generation of Therapeutic. Retrieved Feb. 3 from https://pharmaintelligence.informa.com/resources/product-content/microbiome-modulator-drugs[4] 各大公司官网更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

微生物疗法临床研究

2023-02-11

·药渡Daily

新冠可能引起IBS？IBS的新药研发进展

中国疾病预防控制中心在1月25日发文称新冠感染已过高峰期，自2022年12初以来，各省份报告人群核酸检测阳性数及阳性率呈现先增加后降低趋势，2023年1月23日已降至1.5万。然而，感染新冠病毒之后可能会使感染者出现的长期新冠症状（Long Covid），一项对735,006名患者的荟萃分析显示，出现至少一种症状的COVID-19的合并长新冠患病率为 37.8%。全国在院新冠病毒感染者每日变化情况来源：全国新型冠状病毒感染疫情情况“长期新冠”的症状涉及呼吸系统、神经系统、心血管系统、胃肠系统等多个系统，会产生包括疲劳、焦虑、抑郁、呼吸急促、脑雾、心悸等不同症状。其中消化道症状主要包括腹泻（发病率4.00%）和腹痛（发病率3.82%）。近日，来自意大利研究人员在Gut（IF: 23.06）上发表了一项研究称COVID-19患者的肠易激综合征(irritable bowel disease, IBS)发生率明显高于对照组。GI-COVID-19是一项前瞻性、多中心、对照研究，该研究纳入了2183名住院患者，排除先前存在胃肠道症状和/或手术的情况，主要分析统计883名患者（614名COVID-19患者和269名对照患者）的情况。经1、6、12个月的随访发现，与对照组相比COVID-19患者的胃肠道症状发生率更高，根据罗马IV标准COVID-19 患者报告的IBS发生率也要更高(0.5% vs 3.2%)。12个月随访中肠道-大脑相互作用诊断(DGBI)障碍的患者比例来源：10.1136/gutjnl-2022-328483IBS是最常见的功能性胃肠道疾病之一，其症状包括腹部反复疼痛和排便习惯的改变（可能是腹泻、便秘或两者兼而有之）。根据排便习惯的改变，IBS在临床上可分为以下四种亚型，即腹泻型肠易激综合征（IBS-D)、便秘型肠易激综合征（IBS-C）、混合型肠易激综合征（IBS-M）、未分类型肠易激综合征（IBS-U）。IBS分类来源：Examine.com目前IBS发病机制远未明确，病因包括上皮细胞通透性增加、生态失调、炎症、内脏超敏反应、表观遗传学和遗传学，以及脑-肠相互作用改变等。因发病机制尚未能完全阐明且患者临床表现差别较大，目前已有的IBS治疗方案中的药物主要以对症治疗（便秘、腹泻、腹痛、腹泻等）为主。IBS常用药物IBS全球发病率为9.8%~12.8%，且近年来的患病率有提升趋势，而目前的治疗选择仍存在疗效不显著或者具有较大的副作用等局限性。许多公司正在开发和评估新型肠易激综合征候选药物，以改善治疗前景。临床阶段的IBS药物BEKINDA（Ondansetron）BEKINDA是由RedHill Biopharma开发的一种5-HT3受体拮抗剂Ondansetron的研究性双峰释放、每日给药一次的新制剂，其独特之处在于其能够将速释昂丹司琼与缓释基质相结合，以快速缓解症状，以维持长达24小时的治疗效果。BEKINDA（12mg）已在IBS-D的2期研究中表现出良好的疗效和安全性，RedHill目前正在完成两项关键3期研究的设计。OlorinabOlorinab（APD-371）是Arena发现的候选药物，它是大麻素2型受体（CB2）的完全激动剂。该化合物通过其对CB2与CB1的选择性，可以缓解疼痛而没有精神活性不良反应。一项在273名受试者中进行的随机、双盲、安慰剂对照2b期临床试验结果表明，尽管olorinab耐受性良好，但未达到从基线至第12周总AAPS实现统计学显著改善的主要有效性终点，主要终点是每周平均腹部疼痛评分（AAPS）相对基线的改善情况。使用olorinab治疗的第一周内疼痛有所减轻，并且在第4周和第8周观察到AAPS较基线水平有统计学显著改善。ORP101ORP101是由OrphoMed开发的外周阿片受体μ的部分激动剂以及阿片受体κ的拮抗剂。2018年，ORP-101被FDA授予治疗IBS-D的快速通道认证。ORP-101在治疗IBS-D的双盲、安慰剂对照、II期研究种展现出积极结果。总体而言， ORP-101 100 mg组在II期研究中达到了其主要终点，没有便秘的不良事件，也没有阿片类中枢神经系统效应（欣快感，运动或呼吸效应，醉酒等）。在12周治疗期间内，ORP-101 100 mg对没有胆囊的患者也是安全的。BlautixBlautix是4D pharma开发的一种单株人类肠道共生菌，具有独特的代谢行为，可能允许治疗肠易激综合征。在肠道内，Blautix消耗的气体会引起腹胀、腹痛和排便频率的变化。在II期试验中，Blautix在IBS-C和IBS-D中都表现出了临床活性信号，并且具有高度良好的安全性和耐受性。SK08活菌散SK08活菌散是知易生物基于脆弱拟杆菌（Bacteroides fragilis）开发的LBP药物。2022年12月，SK08活菌散完成了IBS-D上的一项随机、双盲、安慰剂平行对照、多中心、剂量探索的II期临床试验的所有入组和试验。该临床研究的初步结果显示SK08有着非常好的安全性，探索到了剂量关系，观察到了SK08对于IBS-D的有效性，为后续III期临床提供了非常必要的支持。TNP-2092TNP-2092是丹诺医药开发的一个多靶点偶联分子，通过抑制 RNA 聚合酶、DNA 旋转酶和拓扑异构酶IV的多靶点活性产生杀菌作用。TNP-2092口服剂与利福昔明具有类似的药代动力学特性，也是一个胃肠道专属性的药物，具有较低的耐药频率以及更强的抗菌活性。目前，TNP-2092口服剂已经进入II期临床试验。CrofelemerCrofelemer是Napo Pharmaceuticals开发的一种CFTR/CaCC双抑制剂，它是一种植物提取物。在腹泻时，Cl-分泌增多、伴有高容积水的丢失，Crofelemer通过阻断氯离子转运使胃肠道氯离子和水流动正常化。目前Crofelemer在IBS适应症上的开发处于临床II期阶段。RQ-00310941RQ-00310941是RaQualia开发的一种具有高活性和选择性的5-HT2B拮抗剂，该化合物已在动物模型中被证明可有效缓解内脏超敏性引起的疼痛和排便异常问题，而不影响正常排便。目前处于治疗IBS-D的临床I期试验阶段，还没有公布相关临床结果。SMP-100SMP-100是科岭源开发的5-HT3受体部分激动剂，有望在保持对症有效的情况下降低传统拮抗剂的副作用，成为潜在的Best-in-Class药物。在澳洲完成两项临床I期研究中，SMP-100显现出良好的耐受性和优异的安全性，国内I期临床研究仍在进行中。小结-IBS是临床上最常见的功能性胃肠病之一，全球发病率约为9.8%~12.8%，一项统计数据说明新冠感染者的IBS发生率可能更高。-IBS的症状已腹痛、腹胀、排便习惯改变为主，因症状长期存在、病程迁延反复，对患者的生活质量造成严重影响。-因发病机制不明、临床表现差异较大，IBS的用药策略以对症治疗为主。-目前针对IBS的新药研发仍在进行中，国内方面知易生物、丹诺医药和科岭源药业都有临床阶段的IBS管线。参考来源https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202301/t20230125_263519.htmlThe prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022 Dec 1;55:101762.Marasco G, Cremon C, Barbaro MR the GI-COVID19 study group, et alPost COVID-19 irritable bowel syndromeGut Published Online First: 09 December 2022.中华医学会消化病学分会胃肠功能性疾病协作组, 中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见. 中华消化杂志,2020,40 (12): 803-818.END👇关注药渡数据媒体矩阵

临床结果

2022-06-24

·PRNewswire

Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights

SEATTLE, June 24, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global irritable bowel syndrome treatment market is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030). Key Trends and Analysis of the Global Irritable Bowel Syndrome Treatment Market: Major players operating in the market are focusing on conducting workshops to create awareness regarding irritable bowel syndrome, which is expected to drive the market growth over the forecast period. For instance, in May 2018, Allergan plc, a subsidiary of AbbVie Inc., a biopharmaceutical company, and Ironwood Pharmaceuticals, Inc., a healthcare company, announced the launch of the AboutYourGut.com website. The aim of this launch was to help educate sufferers impacted by irritable bowel syndrome with diarrhea (IBS-D), irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), including providing information on condition management. Request Sample Copy of this Report @ Key Market Takeaways: The global irritable bowel syndrome treatment market is expected to exhibit a CAGR of 13.2% during the forecast period due to the increasing adoption of inorganic strategies such as agreements by the key players in the market. For instance, in May 2021, Ironwood Pharmaceuticals, Inc., a healthcare company, and its partner AbbVie Inc., a biopharmaceutical company, reached an agreement with Teva Pharmaceuticals USA, Inc., a multinational pharmaceutical company. As per the terms of this agreement, Teva Pharmaceuticals USA, Inc., would be granted a license to market its 72 mcg generic version of LINZESS, the first prescribed brand in the U.S. for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), in the U.S. beginning March 31, 2029 (subject to U.S. FDA approval), unless certain limited circumstances, customary for settlement agreements of this nature occur. Among medical conditions, the IBS-constipation segment is expected to dominate the segment growth over the forecast period, owing to the increased research and development activities by the key players in the market. For instance, in May 2021, 4D pharma plc., a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced positive data from its completed Phase II trial of LBP Blautix, a single strain live biotherapeutic product (LBP), in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D). On the basis of drug type, the Linaclotide segment is expected to dominate the segment growth over the forecast period, owing to the increasing approvals for linaclotide. For instance, in August 2021, Ironwood Pharmaceuticals, Inc., a healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS (linaclotide) based on clinical safety data that had been generated in pediatric studies. Key players operating in the global irritable bowel syndrome treatment market include Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Request for Customization @ Detailed Segmentation: Global Irritable Bowel Syndrome Treatment Market, By Drug Type: Lubiprostone Linaclotide Eluxadoline Rifaximin Alosetron Other Global Irritable Bowel Syndrome Treatment Market, By Medical Condition: IBS-constipation IBS-diarrhea Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Irritable Bowel Syndrome Treatment Market, By Region: North America By Country: U.S. Canada Europe By Country: U.K. Germany Italy France Spain Russia Rest of Europe Asia Pacific By Country: China India Japan ASEAN Australia South Korea Rest of Asia Pacific Latin America By Country: Brazil Mexico Argentina Rest of Latin America Middle East & Africa By Country: GCC Countries Israel South Africa Rest of Middle East & Africa Buy this Complete Report Now @ Find related trending report below: Short Bowel Syndrome Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [email protected] Website: Follow Us: LinkedIn | Twitter Logo: SOURCE Coherent Market Insights

合作引进/卖出

100 项与 Blautix 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肠易激综合征	临床2期	美国	4D Pharma Plc	2018-10-11
肠易激综合征	临床2期	爱尔兰	4D Pharma Plc	2018-10-11
肠易激综合征	临床2期	英国	4D Pharma Plc	2018-10-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03721107 (BHT-II-002, CTgov)	临床2期	肠易激综合征	366	Blautix (Cohort C: Blautix)	積鑰獵選鹹餘鑰糧醖築(鏇積選憲膚獵廠膚鏇夢) = 獵餘簾鹽鏇艱襯廠顧襯膚觸鏇夢窪鹹鹽廠積鏇 (齋壓願網鏇顧鹹壓構衊, 壓蓋積範膚範顧積餘衊 ~ 鏇願壓鬱襯餘築廠餘憲) 更多	-	2022-01-11
				Placebo (Cohort C: Placebo)	積鑰獵選鹹餘鑰糧醖築(鏇積選憲膚獵廠膚鏇夢) = 鹽窪網夢網醖窪夢顧構膚觸鏇夢窪鹹鹽廠積鏇 (齋壓願網鏇顧鹹壓構衊, 廠鏇鏇鏇艱壓糧製選餘 ~ 製鏇鹽積齋壓選築積衊) 更多
NCT03721107 (BHT-II-002, Corporate Publications) 人工标引	临床2期	肠易激综合征	365	Blautix (76 IBS-C patients and 94 IBS-D)	觸糧觸鏇鏇襯衊膚簾鬱(蓋觸獵膚網獵網壓憲壓) = 範壓鬱壓衊構糧衊遞顧顧鏇鹹艱廠網積廠醖膚 (淵積齋鹽顧獵糧蓋壓簾 ) 更多	积极	2020-10-07
				Placebo (82 IBS-C patients and 101 IBS-D)	觸糧觸鏇鏇襯衊膚簾鬱(蓋觸獵膚網獵網壓憲壓) = 繭鏇蓋願觸蓋餘鹹積淵顧鏇鹹艱廠網積廠醖膚 (淵積齋鹽顧獵糧蓋壓簾 ) 更多